（编辑 姚尧） 证券日报网12月5日讯 科达制造在12月5日回答调研者提问时表示，公司肯尼亚伊新亚陶瓷项目主要生 产规格较大的中高端瓷砖，日产能约1.1万平方米；同时，公司部分陶瓷项目亦在持续开展产品迭代及 升级等技改，但整体大规格瓷砖产能占比仍相对较小。后续，随着当地经济的发展以及瓷砖需求的升 级，公司将根据市场需求逐步推进大规格等高端产品线升级，其亦有望对公司瓷砖产品均价产生正面影 响。 ...

消费电子行业成长性指标 消费电子行业盈利能力指标 消费电子行业财务杠杆指标 消费电子行业 2026 年度信用风险展望（2025 年 11 月） 工商评级一部 丨 宁立杰 候珍珍 崔濛骁 消费电子行业信用风险展望丨 2026 摘要 公司邮箱：lianhe@lhratings.com 网址：www.lhratings.com 电话：010-85679696 传真：010-85679228 地址：北京市朝阳区建国门外大街 2 号中国人保财险大厦 17 层 www.lhratings.com 信用风险展望 0 AI 技术赋能、产品迭代升级、消费高端化趋势是消费电子行 业增长的三大核心驱动力。2025 年前三季度，全球消费电子 行业延续复苏态势，市场规模稳步增长。国家"两新"政策 扩围刺激消费电子产品需求增长。 2025 年前三季度，全球智能手机、PC 与平板电脑行业均呈 现高集中度特征。智能手机行业呈现"高端集中、中低端分 散"的多元化竞争格局，PC 行业头部企业凭借供应链与研发 优势稳固垄断地位，平板电脑行业中国品牌加速崛起，市场 竞争加剧，场景化需求转型为品牌提供了差异化竞争空间。 2025 年前三季度，消费电子 ...

Core Viewpoint - The company is expanding its production capacity by investing in a new manufacturing base for functional oral care products in Jiangsu Province, aiming to enhance operational efficiency and product quality while integrating smart manufacturing technologies [2][4]. Group 1: Project Details - The total investment for the expansion project is estimated at 68.85 million yuan, with construction costs accounting for 45.39 million yuan and equipment and software purchases at 23.46 million yuan [3]. - The project will involve the construction of a six-story factory building with a total area of 22,749 square meters, including a toothpaste production workshop of 18,199 square meters and a hotel slipper production workshop of 4,550 square meters [2][3]. - The construction period is expected to last 14 months, with equipment purchases and capacity integration implemented in phases based on market conditions [3]. Group 2: Business Overview - The company operates in two main sectors: daily chemicals and pharmaceuticals, focusing on the "big consumption, big health" industry [3]. - The daily chemicals segment includes the development, production, and sales of oral care products, personal care items, and hotel supplies, with key brands such as Two-Mouth Needle and Mu Lan Ze [3]. - The pharmaceutical segment produces and sells various medications, including capsules and raw materials, managed by Yikang Pharmaceutical [3]. Group 3: Financial Performance - The Jiangsu company has shown stable operational performance, with projected revenues of 761 million yuan for 2024 and 437 million yuan for the first half of 2025, alongside net profits of 11.95 million yuan and 6.44 million yuan, respectively [3]. - The company has identified a growing need for capacity support and equipment efficiency improvements due to increasing market orders, which has impacted order fulfillment and limited sustainable growth [3][4]. Group 4: Strategic Implications - The project aims to overcome existing capacity bottlenecks by introducing advanced equipment and optimizing production processes, thereby enhancing automation and production efficiency [4]. - The establishment of a hotel slipper production line will reduce reliance on external suppliers and improve product offerings, thereby strengthening market share [4]. - The new facility is expected to provide better conditions for research and innovation, facilitating the iterative upgrade of herbal functional products to meet diverse market demands [4].

Core Viewpoint - The company focuses on the health sector, integrating research, production, and sales of over-the-counter drugs, health foods, and functional foods, while emphasizing innovation and product development to strengthen its market position [1]. Group 1: Business Focus and Strategy - The company is a high-tech enterprise specializing in the health sector, with a relatively small revenue contribution from vitamin C tablets, which has a limited impact on overall performance [1]. - The core business development revolves around vitamin and mineral supplement products, with ongoing research and innovation to enhance product offerings and establish a professional barrier [1]. - The company is advancing its therapeutic OTC medications and probiotics segments to solidify and expand its product moat [1]. Group 2: Future Growth and Profitability - Future strategies include optimizing product structure and improving operational efficiency to enhance profitability [1]. - The company aims to leverage brand advantages and technological accumulation to diversify its product range and strengthen brand building and channel expansion [1]. Group 3: Competitive Positioning - In response to investor inquiries, the company is compared to international health product brands like Redhalo and Swisse, highlighting the need to identify competitive advantages and growth opportunities [3]. - The company faces challenges with a lower gross margin of 35% for vitamin C tablets compared to domestic competitors like Tongrentang, prompting questions on how to increase product premium [3].

Core Viewpoint - The company reported a significant decline in revenue and profit for the first three quarters of 2025, primarily due to the ongoing impact of the alcohol ban and increased expense ratios, indicating a challenging market environment for the liquor industry [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 18.09 billion yuan, a year-on-year decrease of 34.3% [1] - The net profit attributable to shareholders was 3.975 billion yuan, down 53.7% year-on-year [1] - The net profit excluding non-recurring items was 3.757 billion yuan, a decline of 55.3% year-on-year [1] - In Q3 2025, revenue was 3.295 billion yuan, a decrease of 29.0% year-on-year [1] - The net profit attributable to shareholders in Q3 was -369 million yuan, a year-on-year decline of 158.4% [1] - The net profit excluding non-recurring items in Q3 was -475 million yuan, down 204.1% year-on-year [1] Cost and Expense Analysis - The gross margin for Q3 2025 was 53.5%, a decrease of 12.72 percentage points year-on-year [1] - The expense ratios for sales, management, R&D, and financial costs in Q3 were 38.0%, 13.0%, 0.8%, and -1.4%, respectively, with year-on-year increases of 10.23, 2.76, 0.61, and 1.18 percentage points [1] - The total expense ratio increased by 14.78 percentage points year-on-year, reaching 50.4% [1] Market Position and Strategy - The company has a solid foundation for growth, with significant investments in base liquor production and quality improvement over the past decade, resulting in a capacity of 1 million tons of base liquor [3] - The launch of new products, such as the seventh generation of "Hai Zhi Lan" and "Yanghe Daqu" light bottle liquor, indicates a strategic move to enhance market competitiveness [3] - The company aims to leverage its base liquor reserves to drive product upgrades and address consumer choices and channel profit issues [3] Dividend Policy - The company announced a dividend return plan for 2024-2026, committing to a minimum annual dividend of 7 billion yuan, which corresponds to a dividend yield of 6.56% based on the current market capitalization [3] Future Outlook - The company is expected to experience a revenue of 20.349 billion yuan and 20.908 billion yuan in 2025 and 2026, respectively, with a year-on-year decline of 29.5% and a slight increase of 2.7% [4] - The net profit attributable to shareholders is projected to be 4.105 billion yuan and 4.311 billion yuan for 2025 and 2026, reflecting a year-on-year decline of 38.5% and a recovery of 5.0% [4]

Core Insights - The acquisition of the land parcel at a floor price of 2,250 yuan per square meter, totaling 644 million yuan, marks a revitalization of the previously quiet land market in the North Yuhong area [2][4][14] Group 1: Land Acquisition Details - The land parcel, located in Yuhong District, covers an area of 179,025.26 square meters and is designated for residential use (R2) with a maximum floor area ratio of 1.6 [4][6] - The land is currently in a net land state, with a residential tenure of 70 years and commercial tenure of 40 years [4][6] Group 2: Company Strategy and Market Position - Fuyu Real Estate aims to enhance its product offerings and brand influence in the Yuhong area, continuing its 20-year presence in Shenyang [9][11] - The company plans to leverage its successful projects, such as Fuyu Tianxi and Fuyu Jinke Fanmengli, to achieve comprehensive upgrades in planning, design, and community services for the new land parcel [11][13] Group 3: Community and Infrastructure Development - The project is expected to foster a unique community culture and a convenient living environment, providing comprehensive living solutions for homebuyers [13] - Proximity to existing educational resources, such as Qishan No.1 School (Nujiang Branch), will enhance the project's attractiveness by offering immediate access to quality education [15][17]

Core Insights - The company announced advancements in its product line, focusing on the integration of components and improvements in manufacturing processes [1] Group 1: Product Development - The company has iterated its products to the third generation, achieving a weight reduction of 22.5% compared to the previous generation [1] - The surface temperature of the actuator under operational conditions has decreased by 13% [1] - The module size has been reduced by over 30% compared to earlier versions [1] - A next-generation highly integrated module is currently under development, with an expected market launch in the second half of the year [1] Group 2: Customization and Integration - The company is providing customized integration solutions for downstream clients through the industrialization of micro rolling ball screws, micro planetary gear sets, and micro worm gear components [1]

Core Viewpoint - InnoCare (Suzhou) Technology Co., Ltd. plans to issue 20,700,000 new H-shares to enhance its financial strength and support business expansion, with a share price set at HKD 75.58, representing a discount of approximately 7.88% from the last trading price of HKD 82.05 [1][3]. Summary by Sections Share Placement Details - The placement agent aims to secure subscriptions from at least six independent professional and institutional investors [3]. - The new shares represent about 4.1% of the existing issued H-shares and approximately 2.31% of the total issued shares, with post-placement proportions of about 3.94% and 2.26% respectively [3]. Use of Proceeds - The estimated net proceeds from the placement are approximately HKD 1.55 billion, allocated as follows: - Capacity expansion and product upgrades: approximately HKD 482.26 million (31%) to meet the growing demand for GaN power devices and enhance product competitiveness [5]. - Debt repayment: approximately HKD 376.24 million (24%) to optimize capital structure and reduce financial burden [6]. - Working capital and general corporate purposes: approximately HKD 691.93 million (45%), which includes human resources expenses, payments to suppliers, and potential domestic and foreign investments [7]. Share Capital Changes - Post-placement, the company's registered capital and total shares will change to RMB 915,100,653 and 915,100,653 shares respectively [7]. - The company will apply for the listing and trading of the new shares on the Stock Exchange of Hong Kong and will comply with the filing rules of the China Securities Regulatory Commission [7].

Performance Review - In H1 2025, the company achieved operating revenue of 1.496 billion, a year-on-year decrease of 4.03% [1] - The net profit attributable to the parent company was 167 million, down 9.51% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 136 million, a decline of 17.98% year-on-year [1] - The company implemented strategic adjustments to low-efficiency product categories, resulting in a gross margin increase of 1.8 percentage points [1] - Revenue breakdown: Rehabilitation aids contributed 563 million (37.63%), medical care products 424 million (28.32%), and health monitoring products 271 million (18.11%) [1] Growth Potential - Certain core product categories showed strong growth momentum in H1 2025 [1] - Sales of self-developed ventilators increased significantly starting in Q2, along with good performance from blood glucose and uric acid integrated machines, pre-heating thermometers, and home testing strips [1] - Continuous product iteration and channel optimization have strengthened the market position and competitive advantage of core categories, laying a solid foundation for future revenue growth [1] Hearing Aid Business Development - The hearing aid business saw over 20% year-on-year revenue growth in H1 2025 [2] - The company plans to accelerate the implementation of its digital strategy, utilizing a new retail management system to enhance marketing strategies, product structure adjustments, and inventory turnover management [2] - As the proportion of older stores increases, the hearing aid business is expected to gradually turn profitable, potentially becoming the company's second growth curve [2] Profit Forecast - Revenue projections for 2025-2027 are 3.325 billion, 3.794 billion, and 4.316 billion, with year-on-year growth rates of 11.48%, 14.09%, and 13.77% respectively [3] - Expected net profit attributable to the parent company for the same period is 380 million, 466 million, and 548 million, with year-on-year growth rates of 21.79%, 22.63%, and 17.75% respectively [3] - Price-to-earnings ratios for 2025-2027 are projected at 22x, 18x, and 15x, with corresponding PEG ratios of 1.02, 0.80, and 0.87 [3]

Core Viewpoint - The company aims to enhance its research and development, product iteration, and structure optimization to achieve its revenue targets for 2025, focusing on high-value products and project management for domestic and international orders [1] Company Overview - The company, Sai Xiang Technology (002337), is a high-tech enterprise engaged in research, development, production, and trade, specializing in manufacturing various engineering, heavy-duty, passenger, and aviation radial tire production equipment [1] - It also develops industrial control software and network information systems for tire enterprises [1] Achievements - The company has received multiple awards for its technological advancements, including one National Science and Technology Progress First Prize, two Second Prizes, one Third Prize, and several provincial and ministerial First Prizes [1]